Prognostic significance of cyclin D1 and P16 in patients with intermediate-risk head and neck squamous cell carcinoma treated with docetaxel and concurrent radiotherapy

Head and Neck

Volumn 29, Issue 10, 2007, Pages 940-947

  Higuchi, Eisaku ^a   Oridate, Nobuhiko ^a   Homma, Akihiro ^a   Suzuki, Fumiyuki ^a   Atago, Yoshihiro ^a   Nagahashi, Tatsumi ^a   Furuta, Yasushi ^a   Fukuda, Satoshi ^a  

^a HOKKAIDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Concurrent chemoradiotherapy; Cyclin D1; Docetaxel; Head and neck squamous cell carcinoma; P16

Indexed keywords

CYCLIN D1; DOCETAXEL; PROTEIN P16; TUMOR MARKER; ANTINEOPLASTIC AGENT; CYCLIN DEPENDENT KINASE INHIBITOR 2A; TAXOID;

ADULT; ARTICLE; CANCER PATIENT; CANCER STAGING; FEMALE; HEAD AND NECK CARCINOMA; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; SQUAMOUS CELL CARCINOMA; ADJUVANT THERAPY; AGED; CLINICAL TRIAL; HEAD AND NECK TUMOR; METABOLISM; MIDDLE AGED; MORTALITY; PHASE 2 CLINICAL TRIAL; PROPORTIONAL HAZARDS MODEL;

ADULT; AGED; ANTINEOPLASTIC AGENTS; CARCINOMA, SQUAMOUS CELL; CYCLIN D1; CYCLIN-DEPENDENT KINASE INHIBITOR P16; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; MALE; MIDDLE AGED; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RADIOTHERAPY, ADJUVANT; TAXOIDS; TUMOR MARKERS, BIOLOGICAL;

EID: 38449099424     PISSN: 10433074     EISSN: 10970347     Source Type: Journal    
DOI: 10.1002/hed.20632     Document Type: Article

References (38)

1. Pisani P, Parkin DM, Bray F, Ferlay J. Estimates of the worldwide mortality from 25 cancers in 1990. Int J Cancer 1999;83:18-29.
2. Forastiere A, Koch W, Trotti A, Sidransky D. Head and neck cancer. N Engl J Med 2001;345:1890-900.
3. Pignon JP, Bourhis J, Domenge C, Designe L, MACHNC Collaborative Group (Meta-Analysis of Chemotherapy on Head and Neck Cancer). Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data. Lancet 2000;355:949-955.
4. Ringel I, Horwitz SB. Studies with RP 56976 (taxotere): a semisynthetic analogue of taxol. J Natl Cancer Inst 1991;83:288-291.
5. Gueritte-Voegelein F, Guenard D, Lavelle F, Le Goff MT, Mangatal L, Potier P. Relationships between the structure of taxol analogues and their antimitotic activity. J Med Chem 1991;34:992-998.
6. Kim ES, Khuri FR. Docetaxel and radiation as combined-modality therapy. Oncology 2002;16:97-105.
7. Schrijvers D, Vermorken JB. Taxanes in the treatment of head and neck cancer. Curr Opin Oncol 2005;17:218-224.
8. Fujii M, Tsukuda M, Satake B, et al. Japan Cooperative Head and Neck Oncology Group (JCHNOG). Phase I/II trial of weekly docetaxel and concomitant radiotherapy for squamous cell carcinoma of the head and neck. Int J Clin Oncol 2004;9:107-112.
9. Calais G, Bardet E, Sire C, et al. Radiotherapy with concomitant weekly docetaxel for stages III/IV oropharynx carcinoma. Results of the 98-02 GORTEC Phase II trial. Int J Radiat Oncol Biol Phys 2004;58:161-166.
10. Nabell L, Spencer S. Docetaxel with concurrent radiotherapy in head and neck cancer. Semin Oncol 2003;30(Suppl 18):89-93.
11. Piccirillo JF, Feinstein AR. Clinical symptoms and comorbidity: significance for the prognostic classification of cancer. Cancer 1996;77:834-842.
12. Mamelle G, Pampurik J, Luboinski B, Lancar R, Lusinchi A, Bosq J. Lymph node prognostic factors in head and neck squamous cell carcinomas. Am J Surg 1994;168:494-498.
13. Homma A, Furuta Y, Oridate N, et al. Prognostic significance of clinical parameters and biological markers in patients with squamous cell carcinoma of the head and neck treated with concurrent chemoradiotherapy. Clin Cancer Res 1999;5:801-806.
14. Sherr CJ. The Pezcoller lecture: cancer cell cycles revisited. Cancer Res 2000;60:3689.
15. Bellacosa A, Almadori G, Cavallo S, et al. Cyclin D1 gene amplification in human laryngeal squamous cell carcinomas: prognostic significance and clinical implications. Clin Cancer Res 1996;2:175-180.
16. Gleich LL, Li YQ, Wang X, Stambrook PJ, Gluckman JL. Variable genetic alterations and survival in head and neck cancer. Arch Otolaryngol Head Neck Surg 1999;125:949-952.
17. Muller D, Millon R, Velten M, et al. Amplification of 11q13 DNA markers in head and neck squamous cell carcinomas: correlation with clinical outcome. Eur J Cancer 1997;33:2203-2210.
18. Akervall JA, Michalides RJ, Mineta H, et al. Amplification of cyclin D1 in squamous cell carcinoma of the head and neck and the prognostic value of chromosomal abnormalities and cyclin D1 overexpression. Cancer 1997;79:380-389.
19. Capaccio P, Carboni N, Pignataro L, Scotti A, Ottaviani F, Pruneri G. Cyclin D1, p53, mdm2, and Ki67 protein expression in preneoplastic lesions of the larynx. J Chemother 1997;9:113-114.
20. Bova RJ, Quinn DI, Nankervis JS, et al. Cyclin D1 and p16INK4A expression predict reduced survival in carcinoma of the anterior tongue. Clin Cancer Res 1999;5:2810-2819.
21. Lukas J, Parry D, Aagaard L, et al. Retinoblastoma-protein-dependent cell-cycle inhibition by the tumour suppressor p16. Nature 1995;375:503-506.
22. Geradts J, Kratzke RA, Niehans GA, Lincoln CE. Immunohistochemical detection of the cyclin-dependent kinase inhibitor 2/multiple tumor suppressor gene 1 (CDKN2/ MTS1) product p16INK4a in archival human solid tumors: correlation with retinoblastoma protein expression. Cancer Res 1995;55:6006-6011.
23. El-Naggar AK, Lai S, Clayman GL, et al. Expression of p16, Rb, and cyclin D1 gene products in oral and laryngeal squamous carcinoma: biological and clinical implications. Hum Pathol 1999;30:1013-1018.
24. Pande P, Mathur M, Shukla NK, Ralhan R. pRb and p16 protein alterations in human oral tumorigenesis. Oral Oncol 1998;34:396-403.
25. Jares P, Fernandez PL, Nadal A, et al. p16MTS1/CDK4I mutations and concomitant loss of heterozygosity at 9p21-23 are frequent events in squamous cell carcinoma of the larynx. Oncogene 1997;15:1445-1453.
26. Danahey DG, Tobin EJ, Schuller DE, Bier-Laning CM, Weghorst CM, Lang JC. p16 mutation frequency and clinical correlation in head and neck cancer. Acta Otolaryngol 1999;119:285-288.
27. Jayasurya R, Francis G, Kannan S, et al. p53, p16 and cyclin D1: molecular determinants of radiotherapy treatment response in oral carcinoma. Int J Cancer 2004;109:710-716.
28. Hermanek P. Union Internationale Contre le Cancer: TNM classification of malignant tumours. Springer-Verlag: Berlin; 1987. pp 13-29.
29. Kornmann M, Arber N, Korc M. Inhibition of basal and mitogen-stimulated pancreatic cancer cell growth by cyclin D1 antisense is associated with loss of tumorigenicity and potentiation of cytotoxicity to cisplatinum. J Clin Invest 1998;101:344-352.
30. Elbashir SM, Harborth J, Lendeckel W, Yalcin A, Weber K, Tuschl T. Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 2001;411:494-498.
31. Oridate N, Kim HJ, Xu XC, Lotan R. Growth inhibition of head and neck squamous carcinoma cells by small interfering RNAs targeting eIF4E or cyclin D1 alone or combined with cisplatin. Cancer Biol Ther 2005;4:318-323.
32. Boyle JO, Langenfeld J, Lonardo F, et al. Cyclin D1 proteolysis: a retinoid chemoprevention signal in normal, immortalized, and transformed human bronchial epithelial cells. J Natl Cancer Inst 1999;91:373-379.
33. Spinella MJ, Freemantle SJ, Sekula D, Chang JH, Christie AJ, Dmitrovsky E. Retinoic acid promotes ubiquitination and proteolysis of cyclin D1 during induced tumor cell differentiation. J Biol Chem 1999;274:22013-22018.
34. Shintani S, Mihara M, Ueyama Y, Matsumura T, Wong DT. Cyclin D1 overexpression associates with radiosensitivity in oral squamous cell carcinoma. Int J Cancer 2001;96:159-165.
35. Akervall J, Brun E, Dictor M, Wennerberg J. Cyclin D1 overexpression versus response to induction chemotherapy in squamous cell carcinoma of the head and neck-preliminary report. Acta Oncol 2001;40:505-511.
36. Akervall J, Kurnit DM, Adams M, et al. Overexpression of cyclin D1 correlates with sensitivity to cisplatin in squamous cell carcinoma cell lines of the head and neck. Acta Otolaryngol 2004;124:851-857.
37. Homma A, Shirato H, Furuta Y, et al. Randomized phase II trial of concomitant chemoradiotherapy using weekly carboplatin or daily low-dose cisplatin for squamous cell carcinoma of the head and neck. Cancer J 2004;10:326-332.
38. Suzuki F, Nakamaru Y, Oridate N, et al. Prognostic significance of cytoplasmic macrophage migration inhibitory factor expression in patients with squamous cell carcinoma of the head and neck treated with concurrent chemoradiotherapy. Oncol Rep 2005;13:59-64.